ODAC Meeting: Further Restrictions Likely On ESA Use; Changes Advocated by ODAC May Cut Market By 40-50 Percent.
ODAC Member Critical Of Amgen For Price Incentives.
Amgen, J&J Defend ESA Indications.
ODAC Recommends Approval Of Nplate For Thrombocytopenia.
Funding Opportunities: HHMI Commits $300M To Support Early Career Scientists.
Trending Stories
- Rachna Shroff, accomplished GI oncologist and “tireless mentor,” dies at 47
Her endowed award will live on - Oncologist Rachna Shroff endows award to outlast her cancer diagnosis
“Because of my health, I have a profound desire to see this endowment come to fruition now” - Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - VCU’s Baskin and UNC’s Ferris weigh oncology’s looming dilemma—MCDs
Center directors are strategizing for likely FDA approval of GRAIL’s Galleri - As FDA sidesteps the question of Galleri’s clinical benefit, NCI’s Letai has “some concerns”
- As trust in USPSTF erodes, cancer screening is in peril
David Ransohoff predicts a “Wild West” era without evidence-based screening guidelines









